Acelyrin sheds pipeline, lays off 33% of staff three months after CEO departure
Acelyrin is in the rough.
The drug developer that deployed a strategy of in-licensing or acquiring “diamonds in the rough” is now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
